Naurex's NRX-1074 - Rapid Acting Anti-Depressant Positive Results

Naurex Inc., a biopharmaceutical company have announced significant success in their latest trial treating Major Depressive Disorder (MDD) with an introvenous single dose of NRX-1074, an orally active NMDA receptor modulator. What makes this extremely promising for those suffering depression, is that of the approximate 140 study participants, there were no serious adverse affects nor dropouts due to any such effects, combined with a single does efficacy at 24 hours after dosing was 0.88 – more than double the effect size seen with most other antidepressant drugs after four to six weeks of repeated dosing. This means no more daily pill popping compared to a single does oral pill once a month maybe. (adsbygoogle = window.adsbygoogle || []).push({}); Norbert Riedel, Ph.D., president and chief executive officer of Naurex stated: "We are in an advantageous position to have two complementary late-stage assets with compelling clinical data in depression that can serve different needs in cl
https://www.ptsdnews.com/item/4-naurex-s-nrx-1074-rapid-acting-anti-depressant-positive-results